Crinetics Pharmaceuticals Inc’s filing revealed that its Chief Scientific Officer Betz Stephen F. unloaded Company’s shares for reported $3.14 million on Jun 12 ’25. In the deal valued at $32.23 per share,97,483 shares were sold. As a result of this transaction, Betz Stephen F. now holds 99,713 shares worth roughly $3.09 million.
Then, STEPHEN BETZ bought 97,483 shares, generating $3,151,625 in total proceeds.
Before that, Pizzuti Dana sold 2,515 shares. Crinetics Pharmaceuticals Inc shares valued at $86,021 were divested by the Chief Med and Dev Officer at a price of $34.20 per share. As a result of the transaction, Pizzuti Dana now holds 72,233 shares, worth roughly $2.24 million.
Goldman initiated its Crinetics Pharmaceuticals Inc [CRNX] rating to a Neutral in a research note published on July 10, 2025; the price target was $36. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in late March with a ‘”a Buy”‘ rating. TD Cowen began covering CRNX with “Buy” recommendation on February 11, 2025. Wolfe Research started covering the stock on February 04, 2025. It rated CRNX as “a Peer perform”.
Price Performance Review of CRNX
On Monday, Crinetics Pharmaceuticals Inc [NASDAQ:CRNX] saw its stock fall -0.51% to $30.95. Over the last five days, the stock has lost -6.27%. Crinetics Pharmaceuticals Inc shares have fallen nearly -42.53% since the year began. Nevertheless, the stocks have fallen -39.47% over the past one year.
How much short interest is there in Crinetics Pharmaceuticals Inc?
A steep rise in short interest was recorded in Crinetics Pharmaceuticals Inc stocks on 2025-06-13, growing by 0.16 million shares to a total of 10.32 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 10.16 million shares. There was a rise of 1.53%, which implies that there is a positive sentiment for the stock.
